CA2614080C - Anti-ccr7 receptor antibodies for the treatment of cancer - Google Patents

Anti-ccr7 receptor antibodies for the treatment of cancer Download PDF

Info

Publication number
CA2614080C
CA2614080C CA2614080A CA2614080A CA2614080C CA 2614080 C CA2614080 C CA 2614080C CA 2614080 A CA2614080 A CA 2614080A CA 2614080 A CA2614080 A CA 2614080A CA 2614080 C CA2614080 C CA 2614080C
Authority
CA
Canada
Prior art keywords
cells
ccr7
antibody
antibodies
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2614080A
Other languages
English (en)
French (fr)
Other versions
CA2614080A1 (en
Inventor
Cecilia Munoz Calleja
Manuel Jesus Alfonso Perez
Sonia Lopez Giral
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad Autonoma de Madrid
Original Assignee
Universidad Autonoma de Madrid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad Autonoma de Madrid filed Critical Universidad Autonoma de Madrid
Publication of CA2614080A1 publication Critical patent/CA2614080A1/en
Application granted granted Critical
Publication of CA2614080C publication Critical patent/CA2614080C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2614080A 2005-07-06 2006-07-05 Anti-ccr7 receptor antibodies for the treatment of cancer Active CA2614080C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2005/007371 2005-07-06
PCT/EP2005/007371 WO2007003216A1 (en) 2005-07-06 2005-07-06 Anti-ccr7 receptor antibodies for the treatment of cancer
PCT/EP2006/006556 WO2007003426A1 (en) 2005-07-06 2006-07-05 Anti-ccr7 receptor antibodies for the treatment of cancer

Publications (2)

Publication Number Publication Date
CA2614080A1 CA2614080A1 (en) 2007-01-11
CA2614080C true CA2614080C (en) 2014-08-26

Family

ID=36021798

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2614080A Active CA2614080C (en) 2005-07-06 2006-07-05 Anti-ccr7 receptor antibodies for the treatment of cancer

Country Status (16)

Country Link
US (1) US8066996B2 (https=)
EP (1) EP1904102B1 (https=)
JP (1) JP5249025B2 (https=)
KR (1) KR20080030655A (https=)
CN (1) CN101257923A (https=)
AT (1) ATE453407T1 (https=)
AU (1) AU2006265281C1 (https=)
BR (1) BRPI0612632A2 (https=)
CA (1) CA2614080C (https=)
DE (1) DE602006011466D1 (https=)
DK (1) DK1904102T3 (https=)
ES (1) ES2338919T3 (https=)
IL (1) IL188594A (https=)
PT (1) PT1904102E (https=)
RU (1) RU2404808C2 (https=)
WO (2) WO2007003216A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006213686A1 (en) 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy
EP2285403A2 (en) * 2008-05-14 2011-02-23 Msm Protein Technologies, Inc. Human monoclonal antibodies against human chemokine receptor ccr7
US9101559B2 (en) 2009-05-08 2015-08-11 New York University Leukemic cell CNS infiltration controlled by notch-induced chemotaxis
WO2011040428A1 (ja) * 2009-09-29 2011-04-07 学校法人慶應義塾 抗腫瘍剤およびそのスクリーニング方法
AU2011309114B2 (en) * 2010-09-28 2015-03-19 Nb Health Laboratory Co., Ltd. Antihuman CCR7 antibodies, hybridoma, nucleic acid, vector, cell, medicinal composition, and antibody-immobilized carrier
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
EP2970483A2 (en) * 2013-03-15 2016-01-20 Amgen Inc. Methods and compositions relating to anti-ccr7 antigen binding proteins
JP6618191B2 (ja) * 2014-03-27 2019-12-11 国立研究開発法人医薬基盤・健康・栄養研究所 脳マラリアの診断および治療
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
BR112018002877A2 (en) 2015-08-10 2018-11-06 Pepmab B.V. humanized ccr7 receptor antibodies
EP3858993A1 (en) 2015-10-09 2021-08-04 Sarepta Therapeutics, Inc. Compositions and methods for treating duchenne muscular dystrophy and related disorders
WO2018073248A1 (en) 2016-10-17 2018-04-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Prognosis of demyelinating diseases patients and treatment thereof
JOP20190187A1 (ar) * 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
US20220064311A1 (en) * 2018-12-18 2022-03-03 Catapult Therapeutics B.V. The use of anti-CCR7 mabs for the prevention or treatment of graft-versus-host disease (GvHD)
US20230181756A1 (en) * 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
CN119390838B (zh) * 2024-05-29 2025-06-10 锐胜科生物医药(上海)有限公司 一种靶向ccr7的纳米抗体及其制备与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
FR2818747B1 (fr) * 2000-12-26 2003-05-16 Molecular Engines Laboratoires Procede de criblage base sur l'interaction siah-numb
US20020168358A1 (en) * 2001-04-30 2002-11-14 Gladue Ronald P. Treatment of T-cell mediated diseases
DE10248751A1 (de) * 2002-10-18 2004-05-06 Berdel, Wolfgang E., Prof. Dr.med. Dyslokalisationsmoleküle und deren Verwendung
WO2004104574A2 (en) * 2003-05-23 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7)
US7807784B2 (en) * 2003-06-11 2010-10-05 The University Of Chicago Increased T-cell tumor infiltration by mutant LIGHT

Also Published As

Publication number Publication date
DE602006011466D1 (de) 2010-02-11
RU2008104420A (ru) 2009-08-20
AU2006265281C1 (en) 2012-11-15
AU2006265281B2 (en) 2012-03-01
BRPI0612632A2 (pt) 2012-01-03
US20090123483A1 (en) 2009-05-14
ES2338919T3 (es) 2010-05-13
ATE453407T1 (de) 2010-01-15
CN101257923A (zh) 2008-09-03
JP2008545000A (ja) 2008-12-11
JP5249025B2 (ja) 2013-07-31
EP1904102B1 (en) 2009-12-30
IL188594A (en) 2012-02-29
CA2614080A1 (en) 2007-01-11
WO2007003426A1 (en) 2007-01-11
AU2006265281A1 (en) 2007-01-11
US8066996B2 (en) 2011-11-29
DK1904102T3 (da) 2010-04-19
IL188594A0 (en) 2008-04-13
KR20080030655A (ko) 2008-04-04
WO2007003216A1 (en) 2007-01-11
EP1904102A1 (en) 2008-04-02
PT1904102E (pt) 2010-03-29
RU2404808C2 (ru) 2010-11-27

Similar Documents

Publication Publication Date Title
IL188594A (en) Anti-ccr7 receptor antibodies for the treatment of cancer
US9862767B2 (en) Therapeutic methods using anti-CD200 antibodies
KR102048718B1 (ko) 항-cxcr4 항체 및 항체-약물 접합체
US7090843B1 (en) Recombinant anti-CD30 antibodies and uses thereof
CN109069620B (zh) 拮抗剂ccr7受体的人源化抗体
ES2550621T3 (es) Anticuerpos anti-CD19 y usos en oncología
US20080003224A1 (en) Compositions and methods for treating haematological proliferative disorders
KR102338832B1 (ko) Ccr9에 대한 항체 및 그의 적용방법
CN1981868A (zh) 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用
AU2002236519A1 (en) Methods for the prevention and treatment of cancer using anti-C3B(i) antibodies
JP2008507473A (ja) 移植片拒絶におけるｃｄ２０の検出
JP2021521201A (ja) 骨髄異形成症候群を予防または治療するためのｂｓｔ１に対する抗体
HK1124760A (en) Anti-ccr7 receptor antibodies for the treatment of cancer

Legal Events

Date Code Title Description
EEER Examination request
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251028

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260218

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260218